key: cord-0900003-4vvuye8u
authors: Dowell, A. C.; Butler, M. S.; Jinks, E.; Tut, G.; Lancaster, T.; Sylla, P.; Begum, J.; Spalkova, E.; Davies, S.; Pearce, H.; Taylor, G. S.; Syrimi, E.; Baawuah, F.; BECKMANN, J.; OKIKE, I.; Ahmad, S.; GARSTANG, J.; Brent, A.; Brent, B.; Ireland, G.; Aiano, F.; Amin-Chowdhury, Z.; Jones, S.; Borrow, R.; Linley, E.; Poh, J.; Saliba, V.; Amirthalingam, G.; Brown, K.; Ramsay, M.; Zuo, J.; Moss, P.; Ladhani, S.
title: Children develop strong and sustained cross-reactive immune responses against spike protein following SARS-CoV-2 infection
date: 2021-04-19
journal: nan
DOI: 10.1101/2021.04.12.21255275
sha: ceb2d69c6e7e1f74a55bf072948fed7c2224f098
doc_id: 900003
cord_uid: 4vvuye8u

SARS-CoV-2 infection is generally mild or asymptomatic in children but the biological basis for this is unclear. We studied the profile of antibody and cellular immunity in children aged 3-11 years in comparison with adults. Antibody profiles in children were strong with high titres against spike protein and receptor binding domain (RBD). SARS-CoV-2 seroconversion in children strongly boosted antibody responses against seasonal beta-coronaviruses, partly through cross-recognition of the S2 domain, indicating a broad humoral response that was not seen in adults. T cell responses against spike were also >2-fold higher in children compared to adults and displayed a strong Th1 cytokine profile. SARS-CoV-2 spike-reactive cellular responses were present in more than half the seronegative children, indicating pre-existing cross-reactive responses or sensitization against SARS-CoV-2. Importantly, all children retained high antibody titres and cellular responses for more than 6 months after infection whilst relative antibody waning was seen in adults. Children thus distinctly generate robust, cross-reactive and sustained immune responses after SARS-CoV-2 infection with focussed specificity against spike protein. These observations demonstrate several novel features of SARS-CoV-2-specific immune responses in children and may provide insights into relative clinical protection in this group. Such information on the profile of natural infection will help to guide the introduction of vaccination regimens into the paediatric population.

The SARS-CoV-2 pandemic has resulted in over 2.8 million deaths to date and the most significant determinant of outcome is age at the time of primary infection (Booth, Reed et al. 2021) . In children, SARS-CoV-2 infection is generally asymptomatic or mild and contrasts with high rates of hospitalisations and deaths among older adults (Viner, Mytton et al. 2021) . This natural history is unusual for respiratory viruses such as influenza where children are the main drivers of infection and transmission. As such, there is interest in understanding the profile of the immune response to SARS-CoV-2 in children. Studies of SARS-CoV-2-specific immunity in children have been limited to date but initial findings have reported reduced magnitude of both antibody and cellular responses in comparison to adults, and an absence of nucleocapsid-specific antibody responses during or early post-infection (Pierce, Preston-Hurlburt et al. 2020 , Tosif, Neeland et al. 2020 , Weisberg, Connors et al. 2021 . One unique feature of SARS-CoV-2 infection in children is the development of a rare complication, known as Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) also known as paediatric multisystem inflammatory syndrome (MIS-C), which shares features with Kawasaki disease, toxic shock syndrome or both (Consiglio, Cotugno et al. 2020 , Flood, Shingleton et al. 2021 . MIS-C develops approximately 2-6 weeks after infection with median age at 9 years of age (Hoang, Chorath et al. 2020) . The immunological basis for this condition remains unclear but is characterised by diffuse endothelial involvement and broad autoantibody production (Gruber, Patel et al. 2020) .

One potential determinant of differential immune responses to SARS-CoV-2 across the life course may be the timing of exposure to the four additional endemic human coronaviruses (HCoV). These comprise the beta-coronaviruses OC-43 and HKU-1, which have 38% and 35% amino acid homology with SARS-CoV-2, as well as the more distantly related alpha-coronaviruses NL-63 and 229E, each with around 31% homology ( (NCBI) ). All these coronaviruses cause frequent mild childhood infections and antibody seroconversion occurs typically before the age of 5 years. Infection with one of the Alpha or Beta viruses provides short term immunity against re-infection from coronaviruses and believed to represent transient cross-reactive immunity within the subtypes (Dijkman, Jebbink et al. 2008 , Dijkman, Jebbink et al. 2012 , Huang, Garcia-Carreras et al. 2020 ). As such, recent HCoV infection might pre-sensitize children against SARS-CoV-2 infection and may explain cross-reactive SARS-CoV-2neutralising antibodies in some seronegative children (Ng, Faulkner et al. 2020) . Immune responses against HCoV are retained throughout life but do not provide sterilising immunity (Huang, Garcia-Carreras et al. 2020) . Consequently, recurrent infections are common, generating concern that a similar pattern will be observed for SARS-CoV-2 infection. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Covid-19 vaccines are now being implemented widely in adults and vaccine trials in children are currently underway, with the aim of increasing protection across the whole population. It is, therefore, imperative to understand the baseline profile of SARS-CoV-2 specific immune responses in children to inform vaccination strategy. Here we provide a comprehensive characterisation of the convalescent humoral and cellular immune response in a cohort of 92 primary school-aged children compared with 155 adults taking part in SARS-CoV-2 surveillance in the schools (sKIDs) study (Ladhani, Baawuah et al. 2021 ). We demonstrate a markedly different profile of immune response after SARS-CoV-2 infection in children compared to adults. These findings have potential implications for understanding immune responses to infection in children and may provide insights into PIMS-TS. Furthermore, these can also be used to guide and interpret the introduction of COVID-19 vaccination for children.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Public Health England (PHE) initiated prospective SARS-CoV-2 surveillance in primary schools across the UK after they reopened following the easing of national lockdown in June 2020. The protocol for the COVID-19 Surveillance in School KIDs (sKIDs) is available online (https://www.gov.uk/guidance/covid-19-paediatric-surveillance) (Ladhani, Baawuah et al. 2021) .

Surveillance comprised two arms, one involving weekly swabbing of primary school students and staff for SARS-CoV-2 infection (from June to mid-July 2020) and the other comprising swabbing and blood sampling taken in 3 rounds: beginning (1-19 June) and end (3-23 July) of the summer half-term when primary schools were partially re-opened, and after full reopening of all schools in September 2020, at the end of the autumn term (23 November-18 December). Samples for extended humoral and cellular analysis were taken in round 3.

For each known SARS-CoV-2 seropositive individual an age-matched (nearest age in years for students, nearest 10 years for teachers) and gender-matched participant also underwent blood sampling. In total 155 adults and 91 children had sufficient blood sample for serology and cellular responses (Table   1) .

Blood tubes were spun at 300g for 10mins prior to removal of plasma which was then spun again at 800g 10mins and stored at -80°C. Remaining blood was diluted 1:1 with RPMI and PBMC isolated on a Sepmate (Stemcell) density centrifugation tube, washed with RPMI and rested in RPMI+10% FBS overnight at 37°C.

Quantitative IgG antibody titres were measured against trimeric spike (S) protein, nucleocapsid ( 

A total GAM anti-SARS-CoV-2 Spike ELISA kit (Cook, Faustini et al. 2021 ) was purchased from Binding

Site (Birmingham, UK). ELISA was performed following the manufacturer's instructions. Optical density (OD) was compared to a known calibrator and expressed as a ratio to the calibrator. Samples with a ratio above 1.0 were considered sero-positive.

Plasma samples were pre-diluted 1:10 with PBS then pre-absorbed by adding an equal volume of either recombinant Spike S1 domain (10569-CV-100) or Spike S2 (10594-CV-100) (R&D systems) at a concentration of 500ug/ml, in PBS, or PBS alone (mock). Samples were incubated at 37°C for 30min.

Samples were then diluted to a final dilution of 1:5000 in MSD diluent and run on a MSD V-PLEX COVID-19 Respiratory Panel 2 plate in duplicate.

The concentration of antibodies which inhibited interaction between RBD and ACE-2 was determined using a SARS-CoV-2 neutralisation assay (Biolegend), following the manufacturer's instructions.

Briefly, plasma or positive control antibody were pre-incubated with biotinylated-Fc-chimera-S1-RBD protein prior to addition of bead bound ACE-2. Binding of RBD to ACE2 was then measured by the addition of streptavidin-PE. Samples were run on a BD LSR-II flow cytometer and analysed using Legendplex v8.0 software (Biolegend). Results were related to a known RBD neutralising antibody standard and displayed as ng/ml.

Pepmixes pool containing 15-mer peptides overlapping by 10aa from either SARS-CoV-2 Spike S1 or T cell responses were determined using a IFNγ ELISpot Pro kit (Mabtech), as previously described (Zuo, Dowell et al. 2020) . Briefly, standard fresh PBMC were rested over-night prior to assay, 0.25-0.3x10 6 PBMC were added in duplicate per well containing either pep-mix, anti-CD3 (positive) or DMSO (negative) control. Samples were incubated for 16-18hrs. Supernatant was harvested and stored at -All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 80°C. Plates were developed following the manufacturers instructions and read using an AID plate reader (AID). Cut off values were previously determined (Zuo, Dowell et al. 2020) .

Supernatants from donors with a detectable response in overnight Elispot cultures were assessed using a Legendplex Th profile 12-plex kit (BIolegend), following the manufactures instructions. Data was analysed using Legendplex v8.0 Software (Biolegend).

Cryopreserved PBMC were thawed and rested overnight. Cells were then stimulated with a combined Spike-S1, S2 peptide pool at a final concentration of 1μg/ml per peptide, or DMSO (Mock). After 1hr eBiosciecne Protein transport inhibitor cocktail (Thermofisher Scientific) was added and cells incubated for a further 5 hrs. eBioscience Cell stimulation cocktail (Thermofisher Scientific) was used as a positive control. Following stimulation cells were washed (PBS+0.1%BSA), and surface stained at 4°C, 30min. Cells were then washed and fixed in 2% paraformaldehyde. Following washing brilliant staining buffer was added (BD bioscience) and a final concentration of 0.4% Saponin added. Cells were stained intracellularly at room temperature for 30min. Cells were then washed and run on a BD Symphony A3 flow cytometer (BD Biosciences). Antibody details are provided in Extended method table 1.

Statistical tests, including normality tests, were performed as indicated using Graphpad Prism v9 software. Only results found to be significant (p<0.05) are displayed.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint

Blood samples were obtained from 91 children and 154 adults, including 35 children and 81 adults known to be seropositive in previous rounds of testing. The median age of the children was 7 years (range, 3-11) whilst that of adults was 41 years (range, 20-71) in adults. SARS-CoV-2 antibody profile was assessed using the MSD V-plex serology platform to determine serological responses against Spike, Receptor Binding Domain (RBD), N-terminal domain (NTD) and Nucleocapsid (N). In total, 47% of children and 59% of adults were found to be seropositive (Extended Data Table 1) .

Seropositive children and adults demonstrated broadly similar antibody responses against the viral proteins. Geometric mean antibody titres against all four regions, were, however, higher in children, most notably against the NTD and RBD domains, which showed 2.3-fold and 1.7-fold increases respectively although these did not reach statistical significance. ( Figure 1A ). In contrast to previous reports (Weisberg, Connors et al. 2021) we observed a coordinated response against nucleoprotein, with a 1.3-fold increased antibody titre compared to adults (Figure 1 A&B).

Pre-existing immune responses against seasonal coronaviruses might act to modulate clinical outcome following primary SARS-CoV-2 infection, and cross-reactive neutralising antibodies have been reported in SARS-CoV-2-seronegative children (Ng, Faulkner et al. 2020 ). Consequently, we compared antibody levels against the four HCoV in SARS-CoV-2 in seronegative and seropositive children and adults.

A 1.2 to 1.4-fold increase in the titre against HCoV was evident in SARS-CoV-2 seropositive adults compared to the seronegative group. In contrast, antibody levels against all four viruses were markedly higher in SARS-CoV-2 seropositive children, with 2.3, 1.9, 1.5, and 2.1 fold higher antibody levels compared to the seronegative group. These were significant for OC-43 and HKU-1 (p=0.0071, p=0.0024 Brown-Forsythe and Welch ANOVA, with Dunnett's T3 multiple comparison test) ( Figure 2A ).

In order to assess if this effect was specific to HCoV or represented a more general effect of SARS-CoV-2 infection on antibody responses against heterologous infection, we also examined antibody titres against influenza subtypes and respiratory syncytial virus (RSV) in relation to SARS-CoV-2 serostatus.

No significant change in antibody titre against these viruses was seen in either children or adults ( Figure 2B ). These data show that SARS-CoV-2 infection in children strongly and specifically boosts humoral responses against HCoV. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint

Given the large increase in HCoV-specific antibody titre following SARS-CoV-2 infection in children, we were interested to assess to what extent this was cross-reactive against SARS-CoV-2 or could represent a HCoV-specific response. As such, we used recombinant S1 or S2 domains from SARS-CoV-2 to pre-absorb plasma samples prior to assessment of antibody levels to both SARS-CoV-2 and the four HCoV subtypes.

As expected, both the S1 and S2 domains significantly reduced antibody titres against total spike (p<0.0001, p0.0031 respectively, Friedman test with Dunn's multiple comparisons test). The S1

domain but not the S2 domain, absorbed RBD and NTD-specific antibodies against SARS-CoV-2 whilst no influence was observed in relation to nucleocapsid-specific binding for either domain (Figure 3 ). Of note, the S1 domain did not significantly reduce antibody binding to any of the 4 HCoV subtypes indicating little evidence for cross-reactive antibodies against this domain. The S2 domain, however, selectively reduced antibody binding to the two HCoV betacoronaviruses, OC43 and HKU1 (p <0.0001 & p=0.0031, respectively by repeated measure one-way ANOVA with Holm-Sidak's multiple comparison test). No such effect was observed in relation to binding to the alphacoronaviruses NL-63 and 229e ( Figure 3 ).

These data show that the enhanced antibody response to HCoV in children after SARS-CoV-2 infection is based on a combination of antibodies that are cross-reactive against SARS-CoV-2 and those that are specific for HCoV.

We next assessed the magnitude and profile of the cellular immune response against SARS-CoV-2 in children and adults. Elispot analysis against overlapping peptide pools from spike and a combination of nucleocapsid and membrane and envelope (N/M) was performed on samples from 57 children and 93 adults, of which 37 and 64 were seropositive, respectively.

As expected, Elispot responses were common in SARS-CoV-2 seropositive donors, with 86% (32/37) of (Figure 4 B) . The proportion of responders against each pool was also All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint different, with 98% of children with a positive Elispot responding to spike but only 45% responding to the N/M pool. In adults, the proportions were 88% and 64%, respectively (Figure 4 C).

Supernatant samples from the Elispot were then analysed using a multi-analyte bead assay to compare the profile of cytokine production by SARS-CoV-2-specific T cells from children and adults.

Samples from adult donors showed a strong IL-2 response with lower levels of IL-10 production. In contrast, IL-2 levels in samples from children were very low ( Figure 4D ) indicating differential functional response compared with adults. Indeed analysis of three children by flow cytometry indicated that CD8+ IL-2-TNF+IFNγ+ T cells constitute the bulk of the spike-specific T cell response in children (Extended data 2).

Of note, robust cellular responses were also observed in 60% (12/20) seronegative children, all of whom were seronegative by three different serology platforms. Cellular responses of variable but lower magnitude were also present in 34% (10/29) of sero-negative adults (Figure 4 A) . Two children and one adult had anti-nucleocapsid antibodies only on the MSD platform (Extended data Table 2.), but this insufficient to provide definitive sero-status. These cellular responses in seronegative donors were markedly spike-specific, with elevated S:N/M ratios of 7.1 and 5 in children and adults (Figure 4 B), respectively, and may indicate pre-existing cross-reactive immunity. Indeed 7 of 12 seronegative children and 6/10 seronegative adults with a positive ELISpot also had increased antibody levels to one or more HCoV (Extended data Table 2 ) potentially indicating recent HCoV infection. Alternatively, these responses might represent cellular sensitisation to SARS-CoV-2 protein in the absence of seroconversion.

We were next interested to assess the longevity of immune responses within a subgroup of 35 children and 81 adults who had seroconverted at least 6 months prior to analysis. Importantly, all children retained humoral immunity whilst 7% (6/81) of previously seropositive adults failed to show significant antibody responses. Children also maintained higher antibody titres against Spike and RBD which were 1.8-fold higher than adults ( Figure 5A&B ).

The RBD region of spike is the predominant target of neutralising antibodies and as children had strong RBD-specific antibody responses, we next examined relative inhibition of virus binding in an ACE2 binding assay (n=12 children; n=15 adults). A higher, but non-significant, increase in the mean level of neutralising antibody was seen between adults and children ( Figure 5C ). Indicating that both groups maintain antibodies capable of neutralisation of RBD binding to ACE2, although this may be higher in children, consistent with higher RBD antibody levels ( Figure 5A ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. These data show children generate durable cellular and humoral immune responses following natural SARS-Cov-2 infection within an increasing focus against the spike protein.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Age is the primary determinant of the clinical severity of SARS-CoV-2 infection and a life course assessment of virus-specific immunity is essential to understand pathogenesis and design vaccine strategies in children. Our detailed analysis of adaptive immune memory identifies a number of novel features in young children. A key finding was that the magnitude of the adaptive immune response to SARS-CoV-2 is higher in children compared to adults. This is somewhat different to previous reports which have reported lower antibody titres in children. It has also been reported that children do not mount effective antibody responses against nucleocapsid in the early post-infection period. We did observe antibody responses against both spike and nucleocapsid in children but it was also clear that immune responses are much more strongly focussed against spike. This is likely because the spike protein -and RBD in particular -is a major virulence factor for SARS-CoV-2 and antibodies against RBD correlate with neutralising activity in vitro. (Ju, Zhang et al. 2020 ) At the same time, nucleocapsid is a much more abundant protein within the virion and it is possible that the magnitude of the N-specific response is a reflection of peak or aggregate viral load. Levels of virus within the upper airways at the time of primary infection are equivalent in children and adults (Madera, Crawford et al. 2021 ), but relative changes over the course of infection are not known. Enhanced innate immune responses in children may play an important role in limiting systemic replication, which may explain the higher rates of asymptomatic and transient, mild illness in children exposed to the virus compared to adults (Neeland, Bannister et al. 2021) . One striking feature was that SARS-CoV-2 infection in children doubled the antibody titres against all four alpha and beta HCoV subtypes. This pattern was not seen in adults where increased humoral responses were modest, even to the most closely related betacoronavirus (Anderson, Goodwin et al. 2020 , Westerhuis, Aguilar-Bretones et al. 2020 . Of note, increased antibody titres against HoCV have also been observed after SARS-CoV-1 infection (Chan, Cheng et al. 2005) . Using protein domain pre-absorption, we identified that a proportion of this response represented a SARS-CoV-2-specific humoral response that was cross-reactive with the S2 domain of the two more closely-related betacoronaviruses. The S2 domain is more highly conserved than S1 between CoV and this pattern is compatible with preferential targeting of structurallyconserved epitopes by HCoV-specific antibodies in children (Khan, Rahman et al. 2021) . Some studies have shown these to have neutralising activity against SARS-CoV-2 (Shrock et al 2020, Ng et al 2020).

Paediatric SARS-CoV-2 infection, however, also boosts HCoV-specific antibody responses that are not directly cross-reactive, as demonstrated by increased titres against alphacoronaviruses that could not be pre-absorbed. This may potentially reflect weakly cross-reactive B cell clones, potentially activated through T cell cross recognition, and is reminiscent of antibody boosting against H3 haemagglutinin after H1N1 infection in children who have had previous H3N2 infection (Meade, Kuan et al. 2020) . As All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint such, there may be a lower affinity threshold for boosting of related but heterologous immune responses in children which might potentially represent an evolutionary adaptation to expand the memory pool early in life. It is interesting to speculate whether the observation that SARS-CoV-2 infection triggers a broadly reactive humoral response in children might provide insight into the pathophysiology of PIMS-TS, where intense B cell activation and auto-antibody production leads to an inflammatory syndrome. Of note, lack of pre-existing immunity to HCoV is a risk factor for development of PIMS-TS and may potentially indicate a protective influence from a stronger prior cross-reactive memory B cell pool (Consiglio, Cotugno et al. 2020 ).

There is currently very little information regarding the cellular immune response to SARS-CoV-2 in children. Interestingly, we find that the virus-specific T cell response is stronger in children than in adults. Furthermore, the specificity mirrors that of the humoral response in that responses against the spike protein are markedly increased compared to nucleocapsid and envelope proteins.

Virus-specific T cell responses in children also showed a differential cytokine response with markedly reduced production of IL-2 and evidence of increased IL-10 production. This may suggest a more highly differentiated profile in comparison to adults, in line with the enhanced magnitude of the response.

Indeed, IL-2-IFNg+TNF+ CD8 T cell responses represented the majority of the Spike-specific T cell pool observed in three child at 6 months after primary infection. As such further characterisation of the T cell response in children is required.

A further noteworthy feature was that virus-specific T cell responses were detectable in more than half the seronegative children. It is possible that these represent HCoV-specific T cell responses that cross react against SARS-CoV-2 peptides (Mateus, Grifoni et al. 2020 , Nelde, Bilich et al. 2021 , as previously observed for antibody responses that are also focussed against spike protein (Ng et al 2020) . HCoV infections are more common in young children and might potentially lead to generation of effector cells that were detected in the SARS-CoV-2 ELISpot. As such, this profile of cross-reactive antibody and cellular responses in children may help to explain the excellent clinical outcomes in this group. Alternatively, it is possible that these responses represent genuine SARS-CoV-2-specific T cells that have been generated following virus exposure in the absence of antibody sero-conversion. This pattern has been reported in health care workers with high levels of viral exposure (Reynolds, Swadling et al. 2020) and it is possible that such conditions are also seen in primary schools where enforcement of social distancing is challenging.

Many participants were seropositive 6 months prior to analysis and our data extend previous findings in adults (Zuo, Dowell et al. 2020 , Dan, Mateus et al. 2021 ) to show sustained immunity over this time period. Moreover, we also found that children maintained stronger antibody and cellular immune responses at this timepoint compared to adults with no loss of humoral response compared to 7% in All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 adults. These data provide encouragement that immunity generated in childhood may provide longer term protection in the light of increasing concerns that SARS-CoV-2 will become an endemic infection (Shaman and Galanti 2020) . In addition they may indicate a need for less frequent booster vaccination in children.

In conclusion we show that children display a novel and characteristic profile of adaptive immune response against SARS-CoV-2. This is likely to contribute to the strong clinical protection in this age group but may also provide insight into the characteristic immuno-pathology that may develop. Furthermore they will help to guide the introduction and interpretation of vaccine deployment in the paediatric population.

We would like to express our gratitude to the staff, parents and especially children, for their participation in this study, without whom this work would not have been possible.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 /2021 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint Figure 1 

A) SARS-CoV-2 antibody levels determined by MSD assay, serostatus was determined based upon Spike serology and used to divide the cohorts into seropositive (red/blue) and seronegative (light red/blue). Dotted lines represent cut off values for serostatus. Fold change indicates the difference between the geometric mean titres in seropositive children and adults. Bars indicate geometric mean, with 95% CI. B) The level of anti-spike and anti-nucleocapsid were compared within the whole cohorts showing coordinated responses. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint

Antibody titres to the seasonal coronavirus (upper)and other respiratory viruses (lower) by MSD in children (red) and adults (blue) based on serostatus. Fold change indicates the difference between the geometric mean titres in seropositive children and adults. Bars indicate geometric mean, with 95% CI. Only significant differences are shown. Brown-Forsythe and Welch ANOVA, with Dunnett's T3 multiple comparison test. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint

Cross reactive antibodies against Spike 2 domain contribute to increased HCoVspecific antibody responses in SARS-CoV-2 seropositive children Plasma from SARS-CoV-2 seropositive children was assessed for binding to the spike protein of the four HCoV or the Spike, RBD, NTD or nucleocapsid regions of SARS-CoV-2. Plasma was either applied neat (control) or following pre-absorption with either recombinant S1 (Spike 1 Block) or S2 (Spike 2 Block) domain protein. S1 pre-absorption strongly reduced binding to SARS-CoV-2 spike whilst S2 preabsorption reduced binding to OC43 and HKU1. Repeated measure one-way ANOVA with Holm-Sidak's multiple comparison test, or Friedman test with Dunn's multiple comparisons test as appropriate All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Black dots indicate individuals who were seronegative for spike but retained a nucleocapsid antibody response. B) Proportions of individuals retaining antibody responses to antigens as indicated. C) The level of antibodies which neutralise interaction of RBD with the ACE2 protein were determined in children (red) and adults (blue), ten pre-pandemic adult samples were included as a control (black). Dotted line indicates results below limit of detection. Bars indicate geometric mean ±95% CI. D) IFNγ ELISPOT results in children (red) and adults (blue). Black dots indicate individuals who lacked a spike response but retained a nucleocapsid response. , Brown-Forsythe and Welch Anova, with Dunnett's T 3 multiple comparisons test.

E) The proportions of each cohort scored as responding to SARS-CoV-2 is indicated All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 F) The level of spike response was compared to N/M response and displayed as a ratio in seropositive and seronegative adults and children, as indicated. Bars indicate mean. Unpaired t-test.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ;

Validation of cut-offs was tested using plasma samples from nine children (red) and 50 adults (blue) taken prior to CoVID-19. Dotted lines indicate cut-off used. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101/2021.04.12.21255275 doi: medRxiv preprint

PBMC were stimulated for 6hrs in the presence of total-spike peptide pool and then analysed by flow cytometry to assess intracellular cytokine production. A) Gating strategy for analysis. B) Representative example of ICS staining from one child at six months post SARS-CoV-2 infection showing strong TNF+IFNγ+ CD8+ T cell response representing 0.45% of the global CD8+ T cell repertoire.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Retrieved Febuary

Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis

Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63

The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19

Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Human coronavirus NL63 and 229E seroconversion in children

The dominance of human coronavirus OC43 and NL63 infections in infants

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national surveillance

Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

COVID-19 in 7780 pediatric patients: A systematic review

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Distinct antibody repertoires against endemic human coronaviruses in children and adults

SARS-CoV-2 infection and transmission in primary schools in England

Nasopharyngeal SARS-CoV-2 viral loads in young children do not differ significantly from those in older children and adults

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults

Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Will SARS-CoV-2 become endemic

Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19

Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis

Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum

Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies

Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection